Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2079.0
(-3.71%)
JPY 2079.0
(-3.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.94 Billion JPY | 16.05% |
| 2022 | 5.12 Billion JPY | 4.44% |
| 2021 | 4.9 Billion JPY | 0.45% |
| 2020 | 4.88 Billion JPY | 18.32% |
| 2019 | 4.12 Billion JPY | 0.07% |
| 2018 | 4.12 Billion JPY | 4.23% |
| 2017 | 3.95 Billion JPY | 1.23% |
| 2016 | 3.9 Billion JPY | 6.48% |
| 2015 | 3.67 Billion JPY | 3.32% |
| 2014 | 3.55 Billion JPY | 16.48% |
| 2013 | 3.05 Billion JPY | -6.12% |
| 2012 | 3.24 Billion JPY | 7.17% |
| 2011 | 3.03 Billion JPY | 10.59% |
| 2010 | 2.74 Billion JPY | 22.07% |
| 2009 | 2.24 Billion JPY | 2.77% |
| 2008 | 2.18 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.4 Billion JPY | -20.23% |
| 2023 Q3 | 1.29 Billion JPY | -14.4% |
| 2023 Q4 | 1.75 Billion JPY | 36.05% |
| 2023 FY | 5.94 Billion JPY | 16.05% |
| 2023 Q2 | 1.5 Billion JPY | 8.18% |
| 2023 Q1 | 1.39 Billion JPY | 9.94% |
| 2022 Q3 | 1.26 Billion JPY | -3.73% |
| 2022 Q1 | 1.27 Billion JPY | -10.89% |
| 2022 Q2 | 1.31 Billion JPY | 3.14% |
| 2022 FY | 5.12 Billion JPY | 4.44% |
| 2022 Q4 | 1.26 Billion JPY | 0.08% |
| 2021 Q4 | 1.43 Billion JPY | 10.7% |
| 2021 Q1 | 916.24 Million JPY | -32.34% |
| 2021 Q2 | 1.26 Billion JPY | 38.09% |
| 2021 FY | 4.9 Billion JPY | 0.45% |
| 2021 Q3 | 1.29 Billion JPY | 2.16% |
| 2020 Q2 | 1.14 Billion JPY | -4.3% |
| 2020 Q3 | 1.19 Billion JPY | 4.82% |
| 2020 Q4 | 1.35 Billion JPY | 13.25% |
| 2020 Q1 | 1.19 Billion JPY | 2.36% |
| 2020 FY | 4.88 Billion JPY | 18.32% |
| 2019 Q1 | 875.9 Million JPY | -22.75% |
| 2019 FY | 4.12 Billion JPY | 0.07% |
| 2019 Q2 | 1.05 Billion JPY | 20.16% |
| 2019 Q3 | 1.03 Billion JPY | -1.74% |
| 2019 Q4 | 1.16 Billion JPY | 12.62% |
| 2018 Q3 | 919.43 Million JPY | -15.25% |
| 2018 Q2 | 1.08 Billion JPY | 10.0% |
| 2018 Q4 | 1.13 Billion JPY | 23.31% |
| 2018 FY | 4.12 Billion JPY | 4.23% |
| 2018 Q1 | 986.28 Million JPY | 2.11% |
| 2017 Q3 | 1.02 Billion JPY | 10.47% |
| 2017 Q1 | 1.04 Billion JPY | -3.37% |
| 2017 FY | 3.95 Billion JPY | 1.23% |
| 2017 Q4 | 965.94 Million JPY | -5.62% |
| 2017 Q2 | 926.46 Million JPY | -11.02% |
| 2016 Q1 | 893.18 Million JPY | -12.0% |
| 2016 FY | 3.9 Billion JPY | 6.48% |
| 2016 Q4 | 1.07 Billion JPY | 21.9% |
| 2016 Q3 | 883.97 Million JPY | -16.15% |
| 2016 Q2 | 1.05 Billion JPY | 18.03% |
| 2015 FY | 3.67 Billion JPY | 3.32% |
| 2015 Q1 | 959.86 Million JPY | 26.29% |
| 2015 Q4 | 1.01 Billion JPY | 27.05% |
| 2015 Q3 | 798.84 Million JPY | -10.97% |
| 2015 Q2 | 897.29 Million JPY | -6.52% |
| 2014 Q4 | 760.02 Million JPY | -27.63% |
| 2014 Q1 | 849.71 Million JPY | 11.79% |
| 2014 Q2 | 893.12 Million JPY | 5.11% |
| 2014 FY | 3.55 Billion JPY | 16.48% |
| 2014 Q3 | 1.05 Billion JPY | 17.58% |
| 2013 Q4 | 760.08 Million JPY | 10.68% |
| 2013 FY | 3.05 Billion JPY | -6.12% |
| 2013 Q3 | 686.76 Million JPY | -9.33% |
| 2013 Q1 | 845.91 Million JPY | 17.28% |
| 2013 Q2 | 757.44 Million JPY | -10.46% |
| 2012 Q3 | 807.26 Million JPY | -0.42% |
| 2012 FY | 3.24 Billion JPY | 7.17% |
| 2012 Q2 | 810.64 Million JPY | -10.92% |
| 2012 Q1 | 910.01 Million JPY | 11.51% |
| 2012 Q4 | 721.28 Million JPY | -10.65% |
| 2011 Q1 | 713.13 Million JPY | -5.47% |
| 2011 FY | 3.03 Billion JPY | 10.59% |
| 2011 Q2 | 700.03 Million JPY | -1.84% |
| 2011 Q3 | 802.48 Million JPY | 14.63% |
| 2011 Q4 | 816.09 Million JPY | 1.7% |
| 2010 Q1 | 673.68 Million JPY | 0.0% |
| 2010 Q3 | 637.91 Million JPY | -6.3% |
| 2010 FY | 2.74 Billion JPY | 22.07% |
| 2010 Q4 | 754.38 Million JPY | 18.26% |
| 2010 Q2 | 680.78 Million JPY | 1.05% |
| 2009 Q2 | 537.39 Million JPY | 0.0% |
| 2009 FY | 2.24 Billion JPY | 2.77% |
| 2008 FY | 2.18 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 86.377% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.773% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 98.903% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 96.992% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -59.112% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 90.942% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 79.518% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 98.885% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | -12.552% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 90.966% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 87.151% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 48.542% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 27.782% |
| Tsumura & Co. | 48.8 Billion JPY | 87.818% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 82.16% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 69.571% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 90.672% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 53.03% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 85.308% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 86.904% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | -43.012% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | -13.83% |
| MedRx Co., Ltd | 959 Million JPY | -519.917% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -106.874% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -302.778% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -150.774% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 75.398% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 83.222% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -708.644% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 94.044% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -163.369% |